A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213 · Not yet recruiting

Last updated 2026-07-13

This study is testing whether a new drug called elecoglipron can help lower blood sugar levels in adults with type 2 diabetes compared to semaglutide, a currently approved diabetes medication.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1,200 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-07 · est. completion 2028-05

Where 158 sites · Argentina, Australia, Brazil, Bulgaria, Canada, China, Germany, Hungary, Italy, Japan, Poland, South Korea, Taiwan, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT07662213 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

Treatments tested

Elecoglipron Drug

Elecoglipron is administered orally once daily.
Semaglutide Drug

Semaglutide is administered orally once daily.

Main thing measured	Change from baseline in Hemoglobin A1c (HbA1c)
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07662213 ↗